Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2023-08-17 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
上海美迪西生物医药股份有限公司2022年度向特定对象发行A股股票上市公告书
Capital/Financing Update Classification · 95% confidence The document is titled as a "2022年度向特定对象发行A股股票上市公告书" which translates to "2022 Annual Announcement of Specific Object Issuance of A Shares Listing". It details the issuance of new shares to specific investors, including the number of shares, pricing, subscription process, regulatory approvals, underwriting, and allotment results. The document includes extensive information about the issuance process, pricing, investors, regulatory approvals, and share lock-up periods. It is a formal announcement related to a capital raising event through a private placement of shares. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is not a full financial report, earnings release, or regulatory filing of other types, but a detailed announcement of a share issuance and listing. The document length is substantial and contains detailed substantive information about the capital raising event, not just a brief notice or a report publication announcement. Therefore, the correct classification is CAP with high confidence.
2023-08-17 Chinese
美迪西：关于实际控制人及其一致行动人权益变动的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a detailed announcement about changes in the equity holdings of the actual controller and related parties of Shanghai Medicilon Biopharmaceutical Co., Ltd. It includes specific shareholding percentages before and after a stock issuance, details of share transfers and reductions, and compliance with relevant securities laws. The document references a specific equity change event due to a 2022 issuance of A shares and subsequent share reductions. It is not a financial report, earnings release, or management discussion, but rather a formal disclosure of changes in significant share ownership. This fits the definition of a Major Shareholding Notification (MRQ). The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive notification of shareholding changes.
2023-08-17 Chinese
美迪西：2022年度向特定对象发行A股股票发行结果暨股本变动公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the results of a specific share issuance by Shanghai Medicilon Biopharmaceutical Co., Ltd. It includes information on the number of shares issued, pricing, total funds raised, registration and listing details, shareholder changes before and after the issuance, and the impact on company control and governance. It also contains detailed descriptions of the issuance process, regulatory approvals, and the identities of the investors involved. The document is not a financial report like an annual or quarterly report, nor is it a simple announcement of a report publication. It is a comprehensive disclosure about a capital raising event and changes in the capital structure. This fits the definition of a Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a certification. Therefore, the correct classification is CAP with high confidence.
2023-08-17 Chinese
上海美迪西生物医药股份有限公司向特定对象发行股票验资报告
Regulatory Filings
2023-08-10 Chinese
广发证券股份有限公司、中国国际金融股份有限公司关于上海美迪西生物医药股份有限公司2022年度向特定对象发行A股股票发行过程和认购对象合规性的报告
Capital/Financing Update Classification · 100% confidence The document is a detailed report on the process and compliance of a specific issuance of A shares by Shanghai Medicilon Inc. in 2022. It includes information about the issuance method, pricing, number of shares, investors, regulatory approvals, internal decision-making, subscription details, and compliance with relevant laws and regulations. The document is issued by the underwriting securities firms and includes audit and verification statements. It is not a general financial report like an annual or quarterly report, nor is it a simple announcement or proxy statement. It specifically focuses on the issuance process and compliance of a capital raising event through a private placement of shares to specific investors. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and financing activities. The document length is substantial and contains detailed substantive information about the financing event, not just an announcement or summary.
2023-08-10 Chinese
美迪西：关于向特定对象发行A股股票发行情况的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (414 characters) regarding the company's issuance of A shares to specific investors. It mentions that the issuance summary has been filed with the Shanghai Stock Exchange and that the company will proceed with registration and custody of the new shares. It also references a detailed issuance report available on the exchange website. The document does not contain detailed financial data or the full issuance report itself, but rather serves as a notification of the issuance event and related filing. Therefore, it fits the category of a Capital/Financing Update (CAP) rather than the full issuance report or a regulatory filing. The document length and content confirm it is an update on financing activity.
2023-08-10 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.